Vyant Bio Announces Investor Conference Call and Webcast for Second Quarter 2021
August 11, 2021 09:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio to Present at A.G.P.’s Virtual MedTech Summer Conference
July 27, 2021 08:30 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery, is pleased to announce that Jay Roberts,...
Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids
July 13, 2021 08:20 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery technologies, announced today that its...
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
May 17, 2021 17:15 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other...
Vyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021
May 13, 2021 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is focused on integrating human-powered scientific and technology-based systems to...
Vyant Bio to Present at BioNJ’s 11th Annual BioPartnering Conference
May 11, 2021 16:36 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and...
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
April 22, 2021 08:00 ET
|
Vyant Bio, Inc.
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Vyant Bio Announces Newly Appointed Board of Directors
April 05, 2021 16:20 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and...
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX
April 01, 2021 17:45 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and...
Cancer Genetics and StemoniX Announce Merger Closing
March 31, 2021 06:30 ET
|
Cancer Genetics, Inc.
Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc....